Key statistics dashboard for Fate Therapeutics, Inc. (FATE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Stock Data
| Price | $2.44 |
| Market Cap | $284M |
| Enterprise Value | $327.6M |
| Beta | 2.24 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.32 |
| Price / Book | 1.91 |
| P/S | 43.82 |
| EV/EBITDA | -2.80 |
| EV/Sales | 50.48 |
| EV/FCF | -3.10 |
| P/FCF | -2.69 |
| Earnings Yield | -42.89% |
| FCF Yield | -37.15% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -343.01% |
| EBIT Margin | -1947.17% |
| EBITDA Margin | -1805.32% |
| Operating Margin | -2058.08% |
| Net Margin | -1941.09% |
| Return on Equity | -65.08% |
| Return on Assets | -48.44% |
| Return on Invested Capital | -57.47% |
| Return on Capital Employed | -58.72% |
Financial Health
| Current Ratio | 4.85 |
| Quick Ratio | 4.85 |
| Cash Ratio | 0.99 |
| Debt / Equity | 0.49 |
| Debt / Assets | 29.09% |
| Net Debt / EBITDA | -0.37 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -6.97 |
Per-Share Data
| Revenue per share | 0.05 |
| Book Value per share | 1.27 |
| Cash per share | 1.28 |
| FCF per share | -0.88 |
| Tangible Book Value per share | 1.27 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 13 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 31 |
| Avg rating (1-5) | 0.45 |
Related companies: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of FATE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks